

TEST REPORT NO 330188/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Endocalm Nadarra, 60 capsules Batch: ENDNAD/07052025 Production date: 07.05.2025 Expiry date: 07.05.2027		
Sample reception date:	15.05.2025	Sample status: no objections Sample received from the Client		
Start of analysis	28.05.2025			
End of analysis	30.05.2025			
Test report date	30.05.2025			

Test Method	Unit	Result	Criteria	Statement of conformity
# Astaxanthin ¹⁾ PB-2.2 ed. 4 of 10.06.2013				
Astaxanthin	mg/capsule filling	2,40 ± 0,36	-	-
	mg/kg	3636,4 ± 545,4	-	-

1) Capsule filling weight declared by the Client: 660,9 mg.

Test: Astaxanthin was performed in laboratory Laboratorium Badań Produktów Spożywczych, Produktów Barwników i Środowiska Łódź Poland

Authorized by:
ID: 1091, Laboratories Communication Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00

TEST REPORT NO 330191/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Endocalm Nadarra, 60 capsules Batch: ENDNAD/07052025 Production date: 07.05.2025 Expiry date: 07.05.2027		
Sample reception date:	15.05.2025	Sample status: no objections Sample received from the Client		
Start of analysis	20.05.2025			
End of analysis	10.06.2025			
Test report date	10.06.2025			

Test Method	Unit	Result	Criteria	Statement of conformity
# Gamma aminobutyric acid (GABA) ¹⁾ Internal method	mg/dose	216,97 ± 10,85	-	-

1) Dose declared by the Client: 1561,8 mg (2 capsules).

Test: Gamma aminobutyric acid (GABA) was performed in laboratory Certified Laboratories, Inc. Tustin United States of America

Authorized by:
ID: 1091, Laboratories Communication Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00

TEST REPORT NO 330187/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Endocalm Nadarra, 60 capsules Batch: ENDNAD/07052025 Production date: 07.05.2025 Expiry date: 07.05.2027		
Sample reception date:	15.05.2025	Sample status: no objections Sample received from the Client		
Start of analysis	20.05.2025			
End of analysis	11.06.2025			
Test report date	11.06.2025			

Test Method	Unit	Result	Criteria	Statement of conformity
# PEA (Palmitoylethanolamide) ¹⁾ PEA02	mg/capsule	146,79 ± 7,34	-	-

1) Capsule weight declared by the Client: 780,9 mg.

Test: PEA (Palmitoylethanolamide) was performed in laboratory Certified Laboratories, Inc. Tustin United States of America

Authorized by:
ID: 438, Senior Analysis Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00

TEST REPORT NO 330189/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Endocalm Nadarra, 60 capsules Batch: ENDNAD/07052025 Production date: 07.05.2025 Expiry date: 07.05.2027		
Sample reception date:	15.05.2025	Sample status: no objections Sample received from the Client		
Start of analysis	20.05.2025			
End of analysis	11.06.2025			
Test report date	11.06.2025			

Test Method	Unit	Result	Criteria	Statement of conformity
# Trans-resveratrol ¹⁾ SOP 3.1.139	mg/capsule	19,77 ± 0,99	-	-

1) Capsule weight declared by the Client: 780,9 mg.

Test: Trans-resveratrol was performed in laboratory Certified Laboratories, Inc. Tustin United States of America

Authorized by:
ID: 438, Senior Analysis Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00

TEST REPORT NO 330190/25/GDY

Client NADARRA GmbH Harvestehuder Weg 48 20149 Hamburg		Sample (according to declaration of Client) Sample description: Endocalm Nadarra, 60 capsules Batch: ENDNAD/07052025 Production date: 07.05.2025 Expiry date: 07.05.2027		
Sample reception date:	15.05.2025	Sample status: no objections Sample received from the Client		
Start of analysis	28.05.2025			
End of analysis	13.06.2025			
Test report date	13.06.2025			

Test Method	Unit	Result	Criteria	Statement of conformity
# Total soluble proanthocyanidins AOAC 2019.06	g/100 g	2,52 ± 0,50	-	-

Test: Total soluble proanthocyanidins was performed in laboratory Chelab S.r.l. (Siliker) RESANA Italy

Authorized by:
ID: 1091, Laboratories Communication Specialist, Cooperation with Laboratories Section

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

The results refer only to the samples received and tested. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column contains a record: "<" or ">", it means, that it is the test outcome directly related to the lower or upper limit of the measuring range of the method. If an expanded measurement uncertainty is given for such a test outcome, it relates only to the lower or upper limit of the measuring range of the method, respectively. In the case where the Laboratory base on the obtained test outcome, "statement of conformity" column presents an opinion and interpretation. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. The responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl.

* Test method accredited
Test performed by external provider

THE END OF THE REPORT

Page 1 / 1

J.S. HAMILTON POLAND Sp. z o.o.
TESTING LABORATORY
Chwaszczyska 180, 81-571 Gdynia, Poland tel. +48 58 766 99 00